From what 0 stock analysts predict, the share price for Morphic Holding Inc (MORF) might decrease by 100% in the next year. This is based on a 12-month average estimation for MORF. Price targets go from $ to $. The majority of stock analysts believe MORF is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Morphic Holding Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Morphic Holding Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of MORF.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Data Not Found! |
When did it IPO
2019
Staff Count
115
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Praveen P. Tipirneni M.D.
Market Cap
$1.87B
In 2023, MORF generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MORF's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.